Registry of lipid control and the use of lipid-lowering drugs for secondary prevention of cardiovascular events in patients with established atherosclerotic disease in Taiwan: Rationality and methods

International Journal of Gerontology

Volumn 6, Issue 4, 2012, Pages 241-246

  Yin, Wei Hsian ^a,d   Wu, Chau Chung ^b,e   Chen, Jaw Wen ^c,d  

^a CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

atherosclerosis; cardiovascular diseases; lipid management; lipid lowering drugs; risk factors

Indexed keywords

ANTILIPEMIC AGENT;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; DISEASE CONTROL; DISEASE REGISTRY; DYSLIPIDEMIA; HUMAN; LONG TERM CARE; MULTICENTER STUDY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; TAIWAN; TREATMENT OUTCOME;

EID: 84870895857     PISSN: 18739598     EISSN: 1873958X     Source Type: Journal    
DOI: 10.1016/j.ijge.2012.09.001     Document Type: Article

References (50)

1. Department of Health, Executive Yuan, ROC, Taiwan. 2010 Statistics of causes of death in Taiwan. Available from: http://www.doh.gov.tw/CHT2006/DM/DM2- 2-p02.aspx?class-no=440&now-fod-list-no=11468&level-no=1&doc-no= 77184 [accessed 10.04.12].
2. L.Y. Lin, C.H. Lee, and C.C. Yu Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation - a nationwide database analysis Atherosclerosis 217 2011 292 295
3. V.L. Roger, A.S. Go, and D.M. Lloyd-Jones Heart disease and stroke statistics - 2012 update: a report from the American Heart Association Circulation 125 2012 e2 e220
4. World Health Organization The World Health Report 2005-Health Systems: Improving Performance 2005 WHO Geneva
5. R.O. Bonow, L.A. Smaha, and S.C. Smith Jr. World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic Circulation 106 2002 1602 1605
6. W.H. Pan, H.J. Wu, and C.J. Yeh Diet and health trends in Taiwan: comparison of two nutrition and health surveys from 1993-1996 and 2005-2008 Asia Pac J Clin Nutr 20 2011 238 250
7. C.J. Yeh, H.Y. Chang, and W.H. Pan Time trend of obesity, the metabolic syndrome and related dietary pattern in Taiwan: from NAHSIT 1993-1996 to NAHSIT 2005-2008 Asia Pac J Clin Nutr 20 2011 292 300
8. C.H. Tseng, C.K. Chong, and T.T. Chan Optimal anthropometric factor cutoffs for hyperglycemia, hypertension and dyslipidemia for the Taiwanese population Atherosclerosis 210 2010 585 589
9. K.L. Chien, F.C. Sung, and H.C. Hsu Relative importance of atherosclerotic risk factors for coronary heart disease in Taiwan Eur J Cardiovasc Prev Rehabil 12 2005 95 101
10. J.A. Lardizabal, and P. Deedwania Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease Cardiol Clin 29 2011 87 103
11. A. Feher, G. Pusch, and K. Koltai Statin therapy in the primary and the secondary prevention of ischaemic cerebrovascular diseases Int J Cardiol 148 2011 131 138
12. C. Baigent, A. Keech, and P.M. Kearney Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
13. E.J. Mills, B. Rachlis, and P. Wu Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients J Am Coll Cardiol 52 2008 1769 1781
14. P. Amarenco, and J. Labreuche Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention Lancet Neurol 8 2009 453 463
15. Cholesterol Treatment Trialists' (CTT) Collaboration C. Baigent, and L. Blackwell Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
16. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
17. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Circulation 110 2004 227 239
18. S.C. Smith Jr., J. Allen, and S.N. Blair AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute Circulation 113 2006 2363 2372
19. Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) A.L. Catapano, and Z. Reiner ESC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Atherosclerosis 217 Suppl. 1 2011 S1 S44
20. P. Alagona Jr. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy Am J Manag Care 15 Suppl. 3 2009 S65 S73
21. M.J. Chapman, H.N. Ginsberg, and P. Amarenco Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management Eur Heart J 32 2011 1345 1361
22. T.A. Jacobson 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia Int J Clin Pract 65 2011 82 101
23. H.B. Rubins, S.J. Robins, and D. Collins Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N Engl J Med 341 1999 410 418
24. A. Keech, R.J. Simes, and P. Barter Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
25. M. Jun, C. Foote, and J. Lv Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis Lancet 375 2010 1875 1884
26. P.A. McCullough, A.B. Ahmed, and M.T. Zughaib Treatment of hypertriglyceridemia with fibric acid derivatives: impact on lipid subfractions and translation into a reduction in cardiovascular events Rev Cardiovasc Med 12 2011 173 185
27. W.H. Yin, J.J. Wang, and H.L. Jen Low use of statins in patients with acute myocardial infarction: a single center experience Acta Cardiol Sin 23 2007 79 88
28. H.S. Kim, Y. Wu, and S.J. Lin Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study Curr Med Res Opin 24 2008 1951 1963
29. D.D. Waters, C. Brotons, and C.W. Chiang Lipid Treatment Assessment Project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals Circulation 120 2009 28 34
30. C.-F. Hsuan, T.-L. Lee, and H.-L. Chang A retrospective study of statin use and its effectiveness in Taiwanese Acta Cardiol Sin 25 2009 18 25
31. P.S. Yeh, H.J. Lin, and C.H. Bai Effect of in-hospital initiation of lipid-lowering therapy on six-month outcomes in patients with acute ischemic stroke or transient ischemic attack Am J Cardiol 105 2010 1490 1494
32. J.E. Park, C.E. Chiang, and M. Munawar Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey Eur J Prev Cardiol 19 2012 781 794
33. K.-G. Shyu, C.-J. Wu, and G.-Y. Mar Clinical characteristics, management and in-hospital outcomes of patients with acute coronary syndrome - observations from the Taiwan ACS full spectrum registry Acta Cardiol Sin 27 2011 135 144
34. S. Asberg, K.M. Henriksson, and B. Farahmand Ischemic stroke and secondary prevention in clinical practice: a cohort study of 14,529 patients in the Swedish Stroke Register Stroke 41 2010 1338 1342
35. H.J. Lin, W.L. Chang, and M.C. Tseng Readmission after stroke in a hospital-based registry: risk, etiologies, and risk factors Neurology 76 2011 438 443
36. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
37. J. Shepherd, S.M. Cobbe, and I. Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 333 1995 1301 1307
38. S.J. Lewis, L.A. Moye, and F.M. Sacks Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial Ann Intern Med 129 1998 681 689
39. J.R. Downs, M. Clearfield, and S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
40. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group N Engl J Med 339 1998 1349 1357
41. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
42. P.S. Sever, B. Dahlöf, and N.R. Poulter Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the ANGLO-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158
43. J.C. LaRosa, S.M. Grundy, and D.D. Waters Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
44. T.R. Pedersen, O. Faergeman, and J.J. Kastelein High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445
45. J.A. de Lemos, M.A. Blazing, and S.D. Wiviott Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 2004 1307 1316
46. C.P. Cannon, E. Braunwald, and C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
47. S.D. Wiviott, J.A. de Lemos, and C.P. Cannon A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22 Circulation 113 2006 1406 1414
48. P.M. Ridker, E. Danielson, and F.A. Fonseca Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
49. P.M. Ridker, E. Danielson, and F.A. Fonseca Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Lancet 373 2009 1175 1182
50. Prospective Studies Collaboration Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts Lancet 346 1995 1647 1653